secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2023-05-05T23:59:59+00:00
Accession:  0001558370-23-008190
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Editas Medicine Q1 net loss $49M; cash $401.8M; EDIT-301 on track for 20 SCD patients by year-end
--------------------------------------------------------------------------------

- Net loss $49.0M ($0.71 per share), vs $50.5M ($0.74) in Q1 2022; collaboration revenue $9.9M up from $6.8M.
- Cash & equivalents $401.8M as of March 31, 2023; expected to fund operations into 2025.
- 19 SCD patients enrolled in EDIT-301 RUBY trial; on track to dose 20 total by year-end; clinical update at EHA June 2023.
- First TDT patient dosed in EDITHAL trial with successful neutrophil and platelet engraftment; data expected by year-end.
- Appointed Emma Reeve as Board Chair and Elliott Levy as independent director; sold iNK programs to Shoreline Biosciences.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000155837023008190/0001558370-23-008190-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000155837023008190/edit-20230505x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-008190

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer